Debiopharm (Debiopharm Research & Manufacturing), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases and ...
Cartherics and Zucker Institute execute research collaboration and option agreement to combine iPSC-derived NK cell ...
20h
Oligonucleotide CDMO Market worth $11.14 billion by 2031 - Exclusive Report by MarketsandMarkets™
According to MarketsandMarkets™, the Oligonucleotide CDMO Market is projected to reach USD 11.14 billion by 2031 from USD ...
The treatment landscape of hormone receptor–positive, HER2-negative metastatic breast cancer has become increasingly crowded, ...
New license agreement enables an integrated workflow combining antibody labeling, human-relevant 3D testing and quantitative imaging for antibody-based therapeutics Debiopharm (Debiopharm Research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results